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Abstract: Insufficient targeting of the therapeutic genes to tumor cells is one of the major reasons for failure in cancer gene therapy.
Mesenchymal stem cells (MSCs) seem to be a good candidate as a carrier for gene therapy because of its selective tumor tissue-homing
properties. In the current study, we constructed baculoviral vectors (BVs) carrying cytosine deaminase (CD) (BV-CD) or green
fluorescence protein (GFP) genes (BV-GFP) and tested the transduction efficiency of the vectors in tumor and mesenchymal stem cells.
We also tested the in vivo efficacy of the BV-CD vector in a colon cancer model. Our results showed that the recombinant baculoviral
vectors can efficiently transduce mammalian cells and express genes of interest. The BV-CD vector treatment caused significant in vitro
cytotoxicity when used with 5-fluorocytosine. MSCs loaded with the BV-CD vector caused a significant delay in tumor growth and
increased survival when compared to control and MSC alone treated groups bearing colon cancer.
Our results show that the recombinant BV-CD vector could be used either alone or loaded into MSCs in the treatment of established
tumors.
Key words: Gene therapy, mesenchymal stem cells, baculoviral vector, cancer

1. Introduction
Mesenchymal stem cells (MSCs) have important advantages
as vehicles of gene therapy vectors. Recently, MSCs
transduced with lentiviruses, retroviruses, or plasmids
have been successfully tested in cancer treatment studies
(Sasportas et al., 2009; Huang et al., 2010; Matuskova et
al., 2010). Along with bone marrow-derived MSCs (BMMSC), adipose tissue-derived MSCs (AT-MSC) can also
home to tumor sites when administered intravenously
(Elçin, 2003; Kucerova et al., 2007). AT-MSCs transduced
with a retroviral vector carrying the cytosine deaminase
(CD) suicide gene caused significant tumor regression in
a colon cancer model (Ho et al., 2005). Although lentiviral
and retroviral vectors have the capability for long-term gene
expression in transduced cells, the high rate of insertional
mutagenesis limits their use in cancer treatment.
Recently, baculoviral vectors derived from an
insect virus of Autographa californica multiple
nucleopolyhedrovirus have been shown to be used in gene
transfer studies. Ho et al. have shown that the BV can enter
* Correspondence: hakan.akbulut@medicine.ankara.edu.tr

mammalian cells without causing any significant toxicity
(Ho et al., 2005). The BV genome is approximately 130 kb
in size, which allows the transfer of large-sized genes. BVs
have been shown to transduce mammalian cells, including
mesenchymal stem cells (Chuang et al., 2007, 2009; Chen et
al., 2011). The potential of transduction and lack of innate
immunity against baculoviruses in mammals make these
vectors attractive tools for gene targeting and cancer gene
therapy.
In the current study, we constructed baculoviral vectors
carrying CD (BV-CD) or green fluorescence protein (GFP)
genes (BV-GFP) and tested the transduction efficiency of
the vectors in tumor and mesenchymal stem cells. We also
tested the antitumor efficacy of the BM-MSCs transduced
with the BV-CD vector in a colon cancer model.
2. Materials and methods
2.1. Plasmids, cells, and animals
In order to construct the recombinant BV, we used the
following plasmids: pfastBac1 (Invitrogen, Carlsbad, CA,
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USA), pORF-codAupp (InvivoGen, San Diego, CA, USA),
pCITE (2+) (Novagen, Germany), pShuttle-CMVGFP
(Addgene, Teddington, UK), pCR-blunt (Invitrogen),
and pcDNA.1 (Invitrogen). The plasmids were grown
in chemical competent Top 10 E. coli or DH10Bac E.
coli (Invitrogen). Sf-9 insect cells (Invitrogen) were used
to produce baculoviral vectors. HEK293 human renal
epithelial cells (ATCC, Teddington, UK), a mouse colon
cancer cell line (CRL 2638) (ATCC), and primary mouse
mesenchymal stem cells (MSCs) obtained from the bone
marrow of BALB/c mice were used in in vitro transduction
experiments or as vehicles of the recombinant therapeutic
vector in a tumor model. Six- to eight-week-old BALB/c
mice (Refik Saydam Health Institute, Ankara, Turkey)
were used either to obtain BM-MSCs or to establish a colon
cancer model for in vivo experiments. The experimental
protocol was approved by the Animal Experiments Local
Ethics Committee of Ankara University.
2.2. Construction of baculoviral vectors
In the current study, we constructed two different
BVs carrying either the GFP reporter gene or CD
therapeutic gene. The BVs were constructed according
to the manufacturer’s protocol (BAC-to-BAC Baculoviral
Expression System, Invitrogen). Briefly, we first amplified
the CD gene from pORF-codAupp plasmid by using the
forward 5’-ACCATGAGCAA TAACGCTTTACA-3’ and
reverse 5’-GTAACCCAG TCGTTCAACGTTT-3’ primers,
GFP gene using forward 5’-ACGCGCATGCGTAGA
CACACCATGGT
GAGCAAGG-3’
and
reverse
5’-CGGAGGTACCTCGGTCATGGTGGCCT TGT
ACAG-3’ primers, and CMV promoter using forward
5’-ACCACTAGTAA CCGAGTAAGATTTGGC-3’ and
reverse 5’-TTTATGTTTCAGGTTCAG-3’ primers from
pShuttle-CMVGFP plasmid. Then those genes were first
cloned to either pCR blunt or pcDNA.1 shuttle plasmids
and then the genes were cut and cloned to pFastBa/HBMTOPO donor plasmid vector.
The recombinant donor plasmids of pFastBac-CMVGFP or pFastBac-CMV-CD were then transformed into a
DH10Bac competent E. coli. The colonies, including the
right recombination of target genes between the donor
plasmids and the bacmid, were screened and amplified.
Following the purification of the recombinant vectors,
the vector was verified by PCR amplification of the
transgene region between the Tn/R and Tn7L regions
of bacmid by using forward 5’-CCCAGTCACGACGT
TGTAAAACG-3’ and reverse 5’-AGCGGATAACAAT
TTCACACAGG-3’ primers (Airenne et al., 2003).
2.3. Production of baculoviral vector particles
In order to produce baculoviral vector particles, we
transfected the recombinant bacmid plasmids (pfCMVCD, pfCMV-GFP) into Sf-9 cells to produce recombinant
baculovirus (BV-CMV-GFP or BV-CMV-CD) (Figure 1).
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Figure 1. The schematic diagram of the recombinant BV-CMVGFP and BV-CMV-CD vectors.

Briefly, 1 µg of plasmids mixed with transfection reagent
(Cellfectin, Invitrogen, Carlsbad, CA, USA) was added
to Sf-9 cells (5 × 105/well) in unsupplemented Grace’s
Insect Medium (Invitrogen). Following a 5-h period of
incubation at 27 °C, the medium was replaced with 10%
FBS supplemented medium. After a further 72-h period
of incubation, the cells producing viral particles were
collected. Then the recombinant vectors were amplified in
Sf-9 cells. The viral stock was titrated by plaque method
and qPCR amplification of the gp64 gene (baculoQuant
ALL-IN-ONE kit, Oxford Expression Technologies,
Oxford, UK).
2.4. Isolation and expansion of mouse BM-MSCs
MSCs were isolated from the femurs and tibias of 7- to
8-week-old BALB/c mice (n = 12) weighing 20–22 g using
an established technique (Çelebi et al., 2010). The marrow
cells were extracted by injecting Alpha-Minimum Essential
Medium (α-MEM; Hyclone, Logan, UT, USA) containing
100 U/mL penicillin and 100 µg/mL streptomycin (Pen/
Strep; Sigma, St. Louis, MO, USA) into the aseptically
excised and epiphyses removed bones. The supernatant
was washed briefly with PBS and repetitive centrifugation
for 5 min at 1500 rpm. The resulting cell pellet was plated
in 25 cm²-tissue culture flasks (Corning, Costar, New
York, NY, USA) containing α-MEM containing 10% fetal
bovine serum (FBS; Hyclone), and 1% Pen/Strep (complete
medium; CM), and cultured at 37 °C under 5% CO2, 95%
air, and >90% humidity. Unattached cells were removed by
washing the plates with PBS after 72 h, and the culture was
continued with fresh medium changes every other day.
For passaging, cells were detached at ~70% confluence
using 0.05% trypsin/0.53 mM EDTA (pH 7.4; Sigma) and
replated at a density of 104 cells/cm2.
2.5. Immunophenotyping of mouse BM-MSCs
The immunophenotype of the cultured cells (passage
2–4) was determined by flow cytometric analysis with
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FACSCanto II (BD Biosciences, San Jose, CA, USA)
using a CD antigen panel consisting of TER114-PE, Sca1-PE, CD90.2-PE, CD106-PE, CD31-PE, CD45-FITC,
CD11b-FITC, CD44-FITC, and CD29-FITC (all from
BD Biosciences) as described previously (Odabaş et al.,
2014). Briefly, the cells were incubated with conjugated
antibodies, washed twice with FACSCanto II buffer
containing 2% FCS, then fixed in 1% formaldehyde flow
buffer containing 0.1% sodium azide and 0.5% BSA, and
scanned by using the FACSDiva (BD Biosciences) analysis
program.
2.6. Trilineage differentiation of mouse BM-MSCs
The trilineage differentiation potential of mouse BMMSCs was evaluated by differentiating passage-3 cells into
the osteogenic, adipogenic and chondrogenic lineages as
described previously (Çelebi and Elçin, 2009; Odabaş et al.,
2014). While the osteogenic and adipogenic cultures were
performed in 6-well plates, chondrogenic differentiation
was carried out as micropellet culture.
Osteogenic differentiation was induced by switching
to the osteogenic medium consisting of Dulbecco’s
Modified Eagle’s Medium (DMEM; low glucose), 10%
FBS, 50 µM ascorbic acid-2-phosphate (AA), 10 mM
β-glycerophosphate, 0.1 µM dexamethasone (Dex), 1%
L-glutamine, and 1% Pen/Strep (all from Sigma) (Baykan
et al., 2014). Osteogenic culture was continued for 21
days with fresh medium changes every 3 days. The cells
were fixed after 21 days in cold methanol and osteogenic
differentiation was evaluated by immunohistochemistry
using anti-Osteonectin staining (Alexis, San Diego, CA,
USA).
Adipogenic differentiation was carried out for 21 days
in adipogenic medium consisting of high glucose DMEM
supplemented with 10% FBS, 1 μM Dex, 5 μM 3-isobutyl1-methyl-xanthine (IBMX), 5 μM indomethacine, 5 µg/
mL insulin, 1% L-glutamine, and 1% Pen/Strep (all from
Sigma), with fresh medium changes every 3 days. After
21 days, the cells were fixed with 4% paraformaldehyde
(PF; in PBS), washed in PBS and stained for 20 min with
Oil Red O solution (0.16%; Sigma) to evaluate adipogenic
differentiation.
Chondrogenic differentiation was performed on
centrifuged cell pellets (1 × 106 each) inside centrifuge
tubes using chondrogenic medium consisting of high
glucose DMEM supplemented with 10% FBS, 0.1 µM Dex,
50 µM AA, 1 mM sodium pyruvate, 10 ng/mL TGF-β3,
1% insulin-transferrin-selenous acid (ITS) mixture, 1%
L-glutamine, and 1% Pen/Strep (all from Sigma) for 21
days with fresh medium changes every 3 days (Emin et al.,
2008). After 21 days, the cells were fixed in 4% PF, washed
with PBS, and stained with Alcian blue (Sigma) to evaluate
chondrogenic differentiation.

2.7. Transduction of recombinant BVs to mammalian
cells
In order to test the transduction efficiency of the recombinant
BVs we used mouse colon cancer cells (CRL2638) and BMMSCs. Following the culture of the cells on 6-well plates for
12 h, the medium was replaced with fresh medium without
serum. Then the cells were transduced overnight with the
BV-GFP vector at a multiplicity of infection (MOI) of 100.
Following the 12-h incubation with the vector, the medium
was replaced with fresh medium including serum. At the
end of 96-h incubation, the cells were trypsinized and
examined under a fluorescent microscope.
2.8. The protein expression of the CD gene and functional
assay
The CD protein expression of transfected cells was assayed
by western blotting. Briefly, the mouse colon cancer cells
were transduced with the BV-CD vector at the dose of
100 MOI. Following a 72-h period of incubation, the cells
were harvested and analyzed by western blotting. The CD
protein band was determined by using an anti-CD primer
Ab (rat anti-CD IgG1, eBioscience, San Diego, CA, USA)
and a secondary antibody bound to HRP.
To test the function of the CD gene, an XTT cell
proliferation assay was performed (Cell Biolabs Inc, San
Diego, CA, USA). The CRL2638 cells were seeded at a
density of 50,000 cells/well in 96-well plates. The cells were
then exposed to the BV-CD vector at 7 different MOIs
between 0 and 1600 for 12 h. The cells were incubated
for a further 72 h at 500 µM dose of 5-fluorocytosine (5FC). Then 50 μL of XTT (2,3-bis-(2-methoxy-4-nitro-5sulfophenyl)-2H-tetrazolium-5-carboxanilid)
reaction
solution prepared according to the protocol of the
manufacturer was added to the wells and incubated at 37
°C for 2 h. The color change was measured at 450 nm with
a 630 nm reference wavelength on a colorimetric plate
reader.
2.9. In vivo efficacy of the vector
In order to test the in vivo efficacy of the new construct
of chemotherapy sensitizing vector we used a syngeneic
BALB/c colon cancer model. First, 5 × 105 CRL-2638 cells
were suspended in PBS and injected subcutaneously (sc)
into 18 BALB/c mice at 6–8 weeks of age. On the seventh
day of tumor injection, when the tumor nodules in all
mice reached a size of approximately 50 mm3, the mice
were randomly divided into 3 groups with 6 mice in each
and given the assigned treatments. While the first group
(control group) was given intravenous (iv) PBS, the second
group was administered 1 × 105 MSCs and the third group
received 1 × 105 BV-CD vector loaded MSCs (transduced
with the vector at the dose of 100 MOI for 12 h prior
to injection) via the tail vein. On the same day as the iv
injections, we started a 10-day course of intraperitoneal
(ip) therapy (5-FC at 500 mg/kg per day to the assigned
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groups). Tumor sizes were measured every other day and
the tumor volume calculated as volume = length × width/2
(Akbulut et al., 2006).
2.10. Statistical analysis
Results of the in vitro cytotoxicity tests were evaluated
by the Student’s t test using SPSS 10.0 (SPSS, Chicago,
IL, USA). One-way ANOVA (with LSD post-hoc
comparisons) and Mann–Whitney tests were used for the
comparison of tumor volumes. The survival curves were
evaluated by Kaplan–Meier method compared by log-rank
test.
3. Results
3.1. Isolation, expansion, and characterization of BMMSCs
In contrast to human BM-MSCs, mouse BM-MSCs cannot
be easily harvested by attachment to a plastic surface, since
they typically contain significant levels of contaminating
hematopoietic cells. We used a protocol that resulted in
cultures largely composed of pure mouse BM-MSCs; thus
we did not apply an extra immunomagnetic technique
or sorting. The immunophenotypical findings of mouse
BM-MSCs are presented in Figure 2. It was found that
the cells were highly positive to MSC-related antigens,
i.e. CD106-PE (89%), CD44-FITC (100%), CD90.2-PE
(99%), Sca-1-PE (98%), and CD29-pure+FITC (99%). On

the other hand, BM-MSCs were highly negative to CD45FITC (100%), CD11b-FITC (99%), CD31-PE (99%), and
TER119-PE (99%) (Figure 2).
Mouse BM-MSC cultures basically demonstrated
typical bipolar fibroblastoid morphology starting from the
second passage, while we used MSCs from the third and
fourth passages in the transduction studies (Figure 3a).
To fulfill the third standard (described by ISCT) for
defining MSC requirements, we evaluated the in vitro
trilineage mesoderm (namely, osteogenic, chondrogenic,
and adipogenic) differentiation capacity of the cells. Our
findings showed that BM-MSCs could be differentiated
into the osteogenic (Figure 3b), chondrogenic (Figure 3c),
and adipogenic (Figure 3d) lineages in vitro, confirmed by
the anti-Osteonectin, Alcian blue, and Oil red O stainings,
respectively (Figure 3b–3d).
3.2. Recombinant baculoviral vector efficiently
transduced the mammalian cells
We tested the transduction efficacy of the recombinant
vector carrying the GFP gene in Sf-9, CRL-2638, and
MSCs. Following 12-h incubation of the recombinant
vector at the dose of 100 MOI and cells in serum-free
medium, the medium was replaced with fresh medium
supplemented with serum. After 96 h, the GFP positive
cells were determined by fluorescence microscopy. The
recombinant vector transduced almost all of the Sf-9

Figure 2. Immunophenotypical characterization of mouse bone marrow mesenchymal stem cells at the third passage. Cells
were highly positive to the MSC-related antigens, CD106-PE (89%), CD44-FITC (100%), CD90.2-PE (99%), Sca-1-PE (98%),
and CD29-pure+FITC (99%). Cells were highly negative to the following antigens: CD45-FITC (100%), CD11b-FITC (99%),
CD31-PE (99%), and TER119-PE (99%).
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Figure 3. Photomicrographs of mouse bone marrow mesenchymal stem cells in culture and their trilineage differentiation.
(A) Confluent culture at the third passage demonstrating typical bipolar fibroblastoid morphology. (B) Formation of a dense
mineralized ECM typical to osteoblastic cells can be seen by anti-Osteonectin staining after 21 days of osteogenic differentiation.
(C) Accumulation of glycosaminoglycans and some mucopolysaccharides typical to chondrocytes was visualized by Alcian blue
staining after 21 days of chondrogenic differentiation. (D) Adipogenic induction was apparent by the accumulation of lipid-rich
vacuoles within cells, visualized by staining with Oil red O after 21 days (scale bars = 150 µm).

cells (Figure 4a). Although the transduction efficiency in
mammalian cells was lower than in the insect cells (Figures
4b and 4c), approximately 70% of the CRL-2638 cells and
mouse BM-MSCs were GFP positive (Figures 4b and 4c).
3.3. The recombinant BV-CD vector expressed the
enzyme CD in colon cancer cells
Following a 7-h infection of mouse colon cancer cells with
the recombinant BV-CD vector, we detected the CD protein
expression by western blotting (Figure 5a). To test the
functional ability of the CD gene that converts the prodrug
5-FC into a cytotoxic drug 5-FU, we performed an in vitro
cytotoxicity test by using the BV-CD vector. The vector
itself did not cause significant cell death when used alone.
However, the addition of 5-FC caused significant cytotoxicity
at the dose of 100 MOI of the BV-CD vector (Figure 5b).

3.4. In vivo efficacy of the BV-CD vector loaded MSCs
In order to test the in vivo efficacy of the BV-CD vector, we
used a syngeneic BALB/c colon cancer model. First, 5 × 105
CRL-2638 cells were injected sc into BALB/c mice. Three
groups of mice with 6 mice in each having approximately 50
mm3 of tumor nodules were established. The control group
was given iv PBS, the second group iv injection of 1 × 105
BM-MSCs, and the third group iv injection of 1 × 105 BMMSCs loaded with 100 MOI of the BV-CD vector. All the
mice were given ip 500 mg/kg 5-FC in 0.5 mL volume for 10
days. The tumor growth rates of both the control and MSC
treated groups were significantly higher than those of the
BV-CD vector loaded BM-MSCs group (Figure 6a; P < 0.05).
The median overall survival time was significantly
longer in the BV-CD vector loaded BM-MSCs group (19
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Figure 4. Recombinant BVs efficiently express transgene in insect and mammalian cells. Fluorescence imaging of GFP expression
in (A) Sf-9 cells, (B) CRL 2638 cells, (C) mMSCs (scale bars = 100 µm).

days) when compared to either the MSC (14 days) or
control groups (13.0 days) (Figure 6b; P < 0.05).
4. Discussion
Baculoviral vectors have been widely used in the
production of recombinant proteins in insect cells
(Hitchman et al., 2009). Although BVs cannot proliferate
in mammalian cells, they can express the transgenes in
mammalian cells when driven by suitable promoters (Tani
et al., 2003). The human CMV immediate early enhancer
and promoter is the strongest one driving the genes in
almost every mammalian cell (Khan, 2013). The BVs
carrying transgenes driven by CMV have previously been
tested in mammalian tumor models (Wang et al., 2006;
Huang et al., 2008; Swift et al., 2013).

Figure 5. (A) Western blotting of CD protein in CRL 2638 cells.
BV-CD transduced cells produced the CD protein of app. 43 kDA
in size (1: cells transduced with BV-CD; 2: control cells). (B) The
in vitro cytotoxicity of the recombinant BV-CD vector in CRL
2638 cells. The BV-CA/5-FC vector caused significant cell death
100 MOI (P < 0.05) (continuous line).
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We have previously constructed recombinant adenoviral
vectors carrying therapeutic genes driven by the CMV
promoter (Akbulut et al., 2003, 2004). Although adenoviral
vectors are efficient tools for cancer gene therapy, the
immune response against adenoviruses is an important
limiting factor for their therapeutic use in humans (Bessis
et al., 2004). Therefore, in the current study, we aimed
to construct therapeutic baculoviral vectors to avoid the
immune clearance of the therapeutic vector in humans. We
constructed BVs carrying either the GFP gene or a suicide
gene, CD, driven by CMV promoter. The BV-GFP vector
efficiently transduced the mammalian cells. Although the
transduction efficiency was almost 100% in Sf-9 insect
cells at the dose of 100 MOI, it was approximately 70% in
tumor cells and BM-MSCs of the BALB/c mice (Figures
4a–4c). Likewise, the BV-CD vector also caused CD protein
expression in CRL-2638 mouse colon cancer cells (Figure
5a), and the BV-CD/5-FC vector system caused significant
cytotoxicity at the dose of 100 MOI (Figure 5b). Although
we did not use the adenoviral counterpart as the control in
the current study, the in vitro cytotoxicity of the BV-CD/5FC vector system was not as high as that of the adenoviral
ones that we and others have reported before (Akbulut et al.,
2003; Huang et al., 2006; Kaliberova et al., 2008). However,
the lack of toxicity of higher vector particles of the BV-CD
vector at the dose of 1600 MOI in mammalian cells could
be an advantage of this vector in the treatment of human
cancers (Figure 5b, dotted line).
Efficient targeting of gene therapy vectors to tumor cells
is the major hurdle in the treatment of metastatic disease in
humans (Akbulut et al., 2015). In order to achieve a cure
for cancer, the transmission of the therapeutic agents to all
tumor cells is needed in the majority of systemic treatment
modalities in cancer as well as gene therapy. However,
the majority of the first-generation viral vectors have the
inability to target all tumor cells when used systemically
(Bouard et al., 2009). To overcome this, we decided to use
MSCs as vehicles for the newly designed vector. Recently,
MSCs have become popular vehicles in cancer gene
therapy studies (Kucerova et al., 2007; Huang et al., 2010).
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Figure 6. In vivo efficacy of the recombinant BV-CD vector in colon cancer model. (A) Tumor growth rates in assigned treatment
groups (P < 0.05); (B) survival curves of the assigned treatment groups (P < 0.05).

The tumor homing properties of those cells mainly depend
on the chronic inflammatory process induced by the tumor
cells (Sasportas et al., 2009). They can easily home to the
tumor sites when administered intravenously (Kucerova
et al., 2007; Kidd et al., 2009). BVs have been shown to
transduce MSCs in previous reports (Chuang et al., 2009;
Bak et al., 2010). Accordingly, we found that the BV-GFP
vector can enter the MSCs and express the transgene driven
by the CMV promoter (Figure 4). The iv injection of BMMSCs loaded with the BV-CD vector significantly delayed
tumor growth (Figure 6a). Furthermore, the recombinant
vector loaded BM-MSCs increased the median survival

time of the tumor-bearing mice approximately 40% when
compared to either controls or unloaded MSCs (Figure 6b).
Our results show that the recombinant BV-CD vector
could be used either alone or loaded into BM-MSCs in the
treatment of established tumors.
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